Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago,
enormous progress has been made in stem cell biology and regenerative medicine. Human …

Over the past 20 years, and particularly in the last decade, significant developmental
milestones have driven basic, translational, and clinical advances in the field of stem cell …

Oligomeric species populated during the aggregation process of α-synuclein have been
linked to neuronal impairment in Parkinson's disease and related neurodegenerative …

Abstract In 1817, James Parkinson described the symptoms of the shaking palsy, a disease
that was subsequently defined in greater detail, and named after Parkinson, by Jean-Martin …

Parkinson's disease (PD) is the most common movement disorder with motor and nonmotor
signs. The current therapeutic regimen for PD is mainly symptomatic as the etio …

Experimental modelling of human disorders enables the definition of the cellular and
molecular mechanisms underlying diseases and the development of therapies for treating …

Efficient derivation of human cerebral neocortical neural stem cells (NSCs) and functional
neurons from pluripotent stem cells (PSCs) facilitates functional studies of human cerebral …

Protein aggregation causes α-synuclein to switch from its physiological role to a pathological
toxic gain of function. Under physiological conditions, monomeric α-synuclein improves ATP …

In 2017, it is two hundred years since James Parkinson provided the first complete clinical
description of the disease named after him, fifty years since the introduction of high-dose D …

The development of iPSCs reflected the merging of three major scientific streams and has in
turn led to additional new branches of investigation. However, there is still debate about …